Evotec SE announced that the U.S. Department of Defense has awarded Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 74 m for the rapid development of monoclonal antibody -based drug product prototypes targeting orthopoxviruses.
